|[April 10, 2017]
Transgene Announces Upcoming Investor Meetings and R&D Day
Transgene (Paris:TNG) today announced that management will participate
in the upcoming investor events set out below.
Kempen 10th Life Sciences
Conference: April 19, 2017 - Amsterdam, Netherlands
Kepler Biotech Days: June 9, 2017 - Paris, France
Transgene will host a "R&D Day", on June 22, 2017 in Paris, France.
The event which will be conducted in English will feature presentations
from several leading international scientists and clinicians.
Next scheduled financial communication
1st quarter 2017 business update
April 25, 2017 after
Transgene S.A. (Euronext: TNG), part
of Institut M�riux, is a publicly traded French biopharmaceutical
company focused on designing and developing targeted immunotherapies for
the treatment of cancer and infectious diseases. Transgene's programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company's�two lead
clinical-stage programs are: TG4010, a therapeutic vaccine for non-small
cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The
Company has several other programs in clinical and preclinical
development. Transgene is based in Strasbourg, France, and has
additional operations in Lyon, as well as a joint venture in China.
Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter (News - Alert): @TransgeneSA
View source version on businesswire.com: http://www.businesswire.com/news/home/20170410005778/en/
[ InfoTech Spotlight's Homepage ]